Table 3.
Site-Specific Risks of Selected Second Solid Cancers According to Time Since Diagnosis of Testicular Nonseminoma
| Cancer Site and Initial Treatment for Testicular Nonseminoma | Time Since Diagnosis of Testicular Nonseminoma |
Total |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 1 Year |
1-9 Years |
10-19 Years |
≥ 20 Years |
||||||||||||
| No. | SIR | 95% CI | No. | SIR | 95% CI | No. | SIR | 95% CI | No. | SIR | 95% CI | No. | SIR | 95% CI | |
| Bladder* | |||||||||||||||
| Surgery only, no RT | 1 | 4.71 | 0.06 to 26.21 | 3 | 1.34 | 0.27 to 3.93 | 2 | 0.79 | 0.09 to 2.86 | 1 | 0.82 | 0.01 to 4.59 | 7 | 1.13 | 0.45 to 2.33 |
| Chemotherapy, no RT | 0 | 0 | 0 to 23.07 | 0 | 0 | 0 to 2.37 | 7 | 4.01† | 1.61 to 8.26 | 1 | 1.16 | 0.02 to 6.46 | 8 | 1.86 | 0.80 to 3.66 |
| Kidney‡ | |||||||||||||||
| Surgery only, no RT | 1 | 5.62 | 0.07 to 31.26 | 5 | 2.60 | 0.84 to 6.06 | 4 | 1.94 | 0.52 to 4.97 | 1 | 1.04 | 0.01 to 5.77 | 11 | 2.14† | 1.07 to 3.84 |
| Chemotherapy, no RT | 1 | 6.91 | 0.09 to 38.44 | 2 | 1.36 | 0.15 to 4.91 | 7 | 4.52† | 1.81 to 9.31 | 3 | 4.35 | 0.88 to 12.72 | 13 | 3.37† | 1.79 to 5.77 |
| Thyroid§ | |||||||||||||||
| Surgery only, no RT | 2 | 12.17† | 1.37 to 43.93 | 1 | 0.66 | 0.01 to 3.66 | 2 | 1.84 | 0.21 to 6.63 | 0 | 0 | 0 to 9.44 | 5 | 1.58 | 0.51 to 3.69 |
| Chemotherapy, no RT | 0 | 0 | 0 to 25.91 | 8 | 6.51† | 2.80 to 12.83 | 3 | 3.51 | 0.71 to 10.25 | 0 | 0 | 0 to 13.36 | 11 | 4.40† | 2.19 to 7.88 |
| Soft tissue including heart‖ | |||||||||||||||
| Surgery only, no RT | 0 | 0 | 0 to 34.65 | 2 | 2.31 | 0.26 to 8.35 | 1 | 1.81 | 0.02 to 10.05 | 0 | 0 | 0 to 20.25 | 3 | 1.76 | 0.35 to 5.14 |
| Chemotherapy, no RT | 0 | 0 | 0 to 40.48 | 7 | 10.13† | 4.06 to 20.87 | 2 | 4.71 | 0.53 to 17.01 | 1 | 7.77 | 0.10 to 43.24 | 10 | 7.49† | 3.59 to 13.78 |
| Lung and bronchus¶ | |||||||||||||||
| Surgery only, no RT | 0 | 0 | 0 to 8.62 | 5 | 1.11 | 0.36 to 2.60 | 3 | 0.59 | 0.12 to 1.74 | 2 | 0.83 | 0.09 to 2.98 | 10 | 0.81 | 0.39 to 1.49 |
| Chemotherapy, no RT | 0 | 0 | 0 to 11.84 | 0 | 0 | 0 to 1.22 | 6 | 1.70 | 0.62 to 3.71 | 8 | 4.57† | 1.97 to 9.00 | 14 | 1.63 | 0.89 to 2.73 |
NOTE. Histologic types of solid tumors were defined according to International Classification of Diseases for Oncology, Third Edition, as follows: bladder: urothelial carcinoma (8120 and 8130); kidney: papillary adenocarcinoma (8260), clear cell adenocarcinoma (8310), and renal cell carcinoma (8312); thyroid: papillary carcinoma (8050), papillary adenocarcinoma (8260), follicular adenocarcinoma (8330), and papillary carcinoma follicular variant (8340); soft tissue including heart: fibrosarcoma (8810), malignant fibrous histiocytoma (8830), myxoid liposarcoma (8852), squamous cell carcinoma (8070), sarcoma (8800), spindle cell sarcoma (8801), epithelioid sarcoma (8804), mixed type liposarcoma (8855), rhabdomyosarcoma (8900), synovial sarcoma (9040), hemangiosarcoma (9120), and hemangiopericytoma (9150); and lung and bronchus: carcinoma (8010), large-cell carcinoma (8012), small-cell carcinoma (8041), non–small-cell lung carcinoma (8046), squamous cell carcinoma (8070), adenocarcinoma (8140), pleomorphic rhabdomyosarcoma (8901), atypical carcinoid tumor (8249), and meningioma (9530).
Abbreviations: RT, radiotherapy; SIR, standardized incidence ratio.
All bladder cancers comprised transitional cell carcinoma.
SIRs with P < .05.
Histology in the surgery group (n = 11) included one papillary adenocarcinoma (9.1%), four clear cell adenocarcinomas (36.4%), and six renal cell carcinomas (54.5%). Histology in the chemotherapy group (n = 13) included four papillary adenocarcinomas (30.8%), four clear cell adenocarcinomas (30.8%), and five renal cell carcinomas (38.4%).
Histology in the surgery group (n = 5) included one papillary carcinoma (20%), three papillary adenocarcinomas (60%), and one papillary carcinoma with follicular variant (20%). Histology in the chemotherapy group (n = 11) included one papillary carcinoma (9.1%), seven papillary adenocarcinomas (63.6%), one follicular adenocarcinoma (9.1%), and two papillary carcinomas, follicular variant (18.2%).
Histology in the surgery group (n = 3) included one fibrosarcoma (33.3%), one malignant fibrous histiocytoma (33.3%), and one myxoid liposarcoma (33.3%). Histology in the chemotherapy group (n = 10) included one squamous cell carcinoma (10%), one sarcoma (10%), one spindle cell sarcoma (10%), one epithelioid sarcoma (10%), one mixed type liposarcoma (10%), two rhabdomyosarcomas (20%), one synovial sarcoma (10%), one hemangiosarcoma (10%), and one hemangiopericytoma (10%).
Histology in the surgery group (n = 10) included one carcinoma (10%), one large-cell carcinoma (10%), two small-cell carcinomas (20%), one non–small-cell lung carcinoma (10%), one squamous cell carcinoma (10%), three adenocarcinomas (30%), and one pleomorphic rhabdomyosarcoma (10%). Histology in the chemotherapy group (n = 14) included one small-cell carcinoma (7.1%), three non–small-cell lung carcinomas (21.4%), eight adenocarcinomas (57.2%), one atypical carcinoid tumor (7.1%), and one meningioma (7.1%).